

Current Clinical Pathology  
*Series Editor: Antonio Giordano*

Maria M. Picken  
Guillermo A. Herrera  
Ahmet Dogan *Editors*

# Amyloid and Related Disorders

Surgical Pathology and Clinical Correlations

*Second Edition*

 Humana Press

# CURRENT CLINICAL PATHOLOGY

---

ANTONIO GIORDANO, MD, PhD  
Philadelphia, PA, USA

*SERIES EDITOR*

More information about this series at <http://www.springer.com/series/7632>



---

Maria M. Picken • Guillermo A. Herrera  
Ahmet Dogan  
Editors

# Amyloid and Related Disorders

Surgical Pathology and Clinical  
Correlations

Second Edition

 Humana Press

*Editors*

Maria M. Picken, MD, PhD  
Professor of Pathology  
Director of Surgical Pathology  
Loyola University Medical Center  
Department of Pathology  
Maywood, IL, USA

Guillermo A. Herrera, MD  
Albert G. And Harriet G. Smith  
Professor and Chair  
LSU Health Shreveport  
Department of Pathology  
Shreveport, LA, USA

Ahmet Dogan, MD, PhD  
Chief, Hematopathology Service  
Memorial Sloan-Kettering Cancer Center  
Department of Pathology and  
Laboratory Medicine  
New York, NY, USA

ISSN 2197-781X  
Current Clinical Pathology  
ISBN 978-3-319-19293-2  
DOI 10.1007/978-3-319-19294-9

ISSN 2197-7828 (electronic)  
ISBN 978-3-319-19294-9 (eBook)

Library of Congress Control Number: 2015945563

Springer Cham Heidelberg New York Dordrecht London  
© Springer International Publishing Switzerland 2015

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Humana Press is a brand of Springer  
Springer International Publishing AG Switzerland is part of Springer Science+Business Media  
([www.springer.com](http://www.springer.com))

*This book is dedicated to our patients, past and present, with the hope that it will make a difference in the lives of future amyloidosis patients.*

MMP, GAH, AD



---

## Preface (Second Edition)

Amyloidosis, although known since the nineteenth century, retained for a long time the aura of a rare and obscure disease that was untreatable and mainly of purely academic interest. This state of affairs has, however, changed dramatically in recent years. With the new therapies that are now available, patients with systemic light chain amyloidosis (AL) may achieve a durable response and live for more than a decade from the time of their first diagnosis. Treatments for other types of systemic amyloidosis are also improving. Thus, in addition to liver transplantation, patients diagnosed with hereditary amyloidosis derived from a mutant transthyretin (ATTR) are currently being offered pharmacologic therapies that are in clinical trials. However, treatment outcomes are most successful when they are applied early in the disease process. Thus, now more than ever, early diagnosis is of the utmost importance. Although there are a number of excellent amyloidosis treatment centers around the world, early diagnosis of affected patients is reliant upon widespread and effective screening, and, despite advances in laboratory medicine, this still hinges upon the detection of deposits in tissues. Thus, the role of the pathologist in this process is critical. This book therefore has, as its primary focus, the diagnosis of amyloidosis in surgical pathology. Although written primarily for pathologists, it is hoped that this volume will also be helpful to those who would wish to gain insight into recent diagnostic and treatment options.

This second edition of “Amyloid and related disorders” has been expanded to include seven new chapters, while the prior content has been updated. The volume begins with a history of amyloid investigations and the latest nomenclature. Separate chapters are devoted to the mechanism of amyloidogenesis and an overview of AL, AA, ALECT2, hereditary, dialysis, and localized amyloidoses; a brief overview of cerebral amyloidoses is also included. In Part II, diseases that mimic amyloid and related disorders are discussed. Part III is entirely devoted to pathologic diagnosis, including the generic diagnosis of amyloid, and issues pertaining to amyloid typing that involve both antibody-based and proteomic methods. Part IV provides an overview of laboratory support for the diagnosis of amyloidosis, including serum, urine, bone marrow, and genetic studies. Part V provides an overview of amyloid pathologies in the genitourinary tract, cardiac, gastrointestinal/liver, and peripheral nervous systems; new chapters on lymph nodes and spleen, pulmonary, dermal, breast, and iatrogenic amyloidoses have been added.



Part VI discusses clinicopathologic issues and the role of solid organ transplantation, as well as recent advances in therapies for AL, hereditary, and AA amyloidosis. Brief chapters on relevant legal issues, and the patient's perspective, conclude Part VI.

Those who are interested in the amyloidoses are also encouraged to review the contents of "Amyloid: The Journal of Protein Folding Disorders" and contact the International Society of Amyloidosis ([www.amyloidosis.nl](http://www.amyloidosis.nl)). Resources available to patients include the Amyloidosis Foundation (<http://www.amyloidosis.org>) and the Amyloidosis Support Group (<http://www.amyloidosissupport.org>).

It also behooves us to acknowledge that abnormal protein folding, the very essence of amyloid fibril formation, affects many more aspects of our lives than those covered by the chapters in this book. While amyloid formation represents a fundamental process in many diseases and aging, it also plays an important role in vertebrate and invertebrate biology, as functional amyloid; amyloid fibrils also have applications in the fields of nanotechnology and bioengineering. Therefore, understanding the driving forces behind both the regulated and unregulated formation of amyloid structures may help us to enlist that knowledge in the fight against disease and the aging process and may, unexpectedly, also lead to improvements in many other areas of our lives.

Maywood, IL, USA  
Shreveport, LA, USA  
New York, NY, USA

Maria Mrozowicz Picken  
Guillermo A. Herrera  
Ahmet Dogan

---

## Acknowledgments

The editors would like to express their gratitude to the contributing authors and the publisher, Springer, and its Editors, Richard A. Hruska, Senior Editor, Clinical Medicine, and Michele Aiello, Developmental Editor, for editorial support during the publication process. Special thanks are due to Roger N. Picken for extensive editorial help.



---

# Contents

## Part I Introduction/General

- 1 Aspects of the History and Nomenclature of Amyloid and Amyloidosis**..... 3  
Per Westermark
- 2 Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis**..... 9  
Mario Nuvolone, Giovanni Palladini, and Giampaolo Merlini
- 3 AA Amyloidosis** ..... 31  
Amanda K. Ombrello and Ivona Aksentijevich
- 4 Leukocyte Cell-Derived Chemotaxin 2 Amyloidosis (ALECT2)** ..... 55  
Oana Madalina Mereuta, Chris P. Larsen, and Ahmet Dogan
- 5 The Hereditary Amyloidoses**..... 65  
Merrill D. Benson
- 6 Dialysis-Associated Amyloidosis** ..... 81  
Paweena Susantitaphong, Laura M. Dember, and Bertrand L. Jaber
- 7 Localized Amyloidoses and Amyloidoses Associated with Aging Outside the Central Nervous System**..... 95  
Per Westermark
- 8 Amyloid Deposition in the Central Nervous System** ..... 121  
Fausto J. Rodriguez, Maria M. Picken, and John M. Lee

## Part II Non-amyloid Protein Deposits

- 9 Differential Diagnosis of Amyloid in Surgical Pathology: Organized Deposits and Other Materials in the Differential Diagnosis of Amyloidosis**..... 135  
Guillermo A. Herrera and Elba A. Turbat-Herrera
- 10 Light/Heavy Chain Deposition Disease as a Systemic Disorder** ..... 153  
Guillermo A. Herrera and Elba A. Turbat-Herrera

<b>11 Non-Randall Glomerulonephritis with Non-Organized Monoclonal Ig Deposits .....</b>	<b>167</b>
Pierre Ronco, Alexandre Karras, and Emmanuelle Plaisier	
<b>12 Pathologies of Renal and Systemic Intracellular Paraprotein Storage: Crystallopathies and Beyond .....</b>	<b>179</b>
Maria M. Picken and Ahmet Dogan	
<b>Part III Diagnosis</b>	
<b>13 Diagnosis of Amyloid Using Congo Red.....</b>	<b>197</b>
Alexander J. Howie	
<b>14 Diagnosis of Minimal Amyloid Deposits by Congo Red Fluorescence and Amyloid Type-Specific Immunohistochemistry: A Review.....</b>	<b>213</b>
Reinhold P. Linke	
<b>15 Thioflavin T Stain: An Easier and More Sensitive Method for Amyloid Detection.....</b>	<b>225</b>
Maria M. Picken and Guillermo A. Herrera	
<b>16 Fat Tissue Analysis in the Management of Patients with Systemic Amyloidosis .....</b>	<b>229</b>
Johan Bijzet, Ingrid I. van Gameren, and Bouke P.C. Hazenberg	
<b>17 Generic Diagnosis of Amyloid: A Summary of Current Recommendations and the Editor's Comments on Chapters 13–16 .....</b>	<b>249</b>
Maria M. Picken	
<b>18 Typing of Amyloid for Routine Use on Formalin-Fixed Paraffin Sections of 626 Patients by Applying Amyloid type-Specific Immunohistochemistry: A Review.....</b>	<b>261</b>
Reinhold P. Linke	
<b>19 Amyloid Typing: Experience from a Large Referral Centre .....</b>	<b>273</b>
Janet A. Gilbertson, Julian D. Gillmore, and Philip N. Hawkins	
<b>20 Options for Amyloid Typing in Renal Pathology: The Advantages of Frozen Section Immunofluorescence and a Summary of General Recommendations Regarding Immunohistochemistry Methods.....</b>	<b>283</b>
Maria M. Picken	
<b>21 Amyloid Typing in Plastic-Embedded Tissue by Immune-Gold-Silver Method.....</b>	<b>295</b>
Anne Räisänen-Sokolowski and Tom Törnroth	

<b>22</b>	<b>The Role of Immuno-Electron Microscopy in Amyloid Typing: The Experience of the Pavia Referral Center</b> .....	299
	Laura Verga, Patrizia Morbini, Giovanni Palladini, Laura Obici, Gian Luca Capello, Marco Paulli, and Giampaolo Merlini	
<b>23</b>	<b>Classification of Amyloidosis by Mass Spectrometry-Based Proteomics</b> .....	311
	Ahmet Dogan	
<b>24</b>	<b>The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center</b> .....	323
	Francesca Lavatelli, Francesca Brambilla, Andrea Di Fonzo, Giovanni Ferraro, Giovanni Palladini, Pierluigi Mauri, and Giampaolo Merlini	
<b>Part IV Ancillary Studies of Amyloidosis</b>		
<b>25</b>	<b>Laboratory Support for Diagnosis of Amyloidosis</b> .....	333
	David L. Murray and Jerry A. Katzmann	
<b>26</b>	<b>Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis</b> .....	343
	John C. Lee, Lawreen H. Connors, and Carl J. O’Hara	
<b>27</b>	<b>Laboratory Methods for the Diagnosis of Hereditary Amyloidoses</b> .....	355
	S. Michelle Shiller, Ahmet Dogan, Kimiyo M. Raymond, and W. Edward Highsmith Jr.	
<b>Part V Organ Involvement in Amyloidoses</b>		
<b>28</b>	<b>Amyloidoses of the Kidney, the Lower Urinary and Genital Tracts (Male and Female), and the Breast</b> .....	369
	Maria M. Picken and Ahmet Dogan	
<b>29</b>	<b>Cardiac Amyloidosis</b> .....	391
	Carmela D. Tan and E. Rene Rodriguez	
<b>30</b>	<b>Amyloidosis of the Gastrointestinal Tract and Liver</b> .....	413
	Oscar W. Cummings and Merrill D. Benson	
<b>31</b>	<b>Peripheral Nerve Amyloidosis</b> .....	437
	Adam J. Loavenbruck, JaNean K. Engelstad, and Christopher J. Klein	
<b>32</b>	<b>Amyloidosis of the Lymph Nodes and the Spleen</b> .....	451
	Filiz Sen and Ahmet Dogan	

<b>33 Amyloidosis of the Lung</b> .....	459
Karen L. Grogg, Oana Madalina Mereuta, and Ahmet Dogan	
<b>34 Cutaneous Amyloidosis</b> .....	469
Oana Madalina Mereuta and Ahmet Dogan	
<b>35 Iatrogenic Pharmaceutical Amyloidosis Associated with Insulin and Enfuvirtide Administration</b> .....	481
Ahmet Dogan and Oana Madalina Mereuta	
<b>Part VI Clinical Issues and Therapy</b>	
<b>36 Clinical and Pathologic Issues in Patients with Amyloidosis: Summary and Practical Comments Regarding Diagnosis, Therapy, and Solid Organ Transplantation</b> .....	489
Maria M. Picken and Kevin Barton	
<b>37 Emerging Therapies for Amyloidosis</b> .....	507
Merrill D. Benson	
<b>38 Modern Therapies in AA Amyloidosis</b> .....	513
Amanda K. Ombrello	
<b>39 Medicolegal Issues of Amyloidosis</b> .....	519
Timothy Craig Allen	
<b>40 Amyloidosis from the Patient’s Perspective</b> .....	525
Muriel Finkel	
<b>Index</b> .....	531

---

## Contributors

**Ivona Aksentijevich, MD** Inflammatory Disease Section, National Institutes of Health, National Human Genome Research Institute, Bethesda, MD, USA

**Timothy Craig Allen, MD, JD** Department of Pathology, The University of Texas Medical Branch, Galveston, TX, USA

**Kevin Barton, MD** Division of Hematology/Oncology, Loyola University Medical Center, Maywood, IL, USA

**Merrill D. Benson, MD** Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Van Nuys Medical Science Building, Indianapolis, IN, USA

**Johan Bijzet, BSc** Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

**Francesca Brambilla, PhD** Department of Proteomics and Metabolomics, Institute for Biomedical Technologies (ITB-CNR), Segrate (MI), Italy

**Gian Luca Capello, BS** Foundation IRCCS Policlinico San Matteo, Pavia, Italy

Department of Molecular Medicine, University of Pavia, Pavia, Italy

**Lawreen H. Connors, PhD** Departments of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA

Amyloidosis Center, Boston University School of Medicine, Boston, MA, USA

**Oscar W. Cummings, MD** Department of Pathology, Indiana University Health, Indianapolis, IN, USA

**Laura M. Dember, MD** Renal, Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

**Andrea Di Fonzo, PhD** Department of Molecular Medicine and Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy



**Ahmet Dogan, MD, PhD** Departments of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**JaNean K. Engelstad, MS** Peripheral Nerve Laboratory, Mayo Clinic, Rochester, MN, USA

**Giovanni Ferraro, MSc** Department of Molecular Medicine and Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

**Muriel Finkel** Amyloidosis Support Groups, Wood Dale, IL, USA

**Janet A. Gilbertson, CSci, FIBMS** UCL Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, London, UK

**Julian D. Gillmore, MBBS, MD, PhD, FRCP** UCL Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, London, UK

**Karen L. Grogg, MD** Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

**Philip N. Hawkins, PhD, FRCP, FRCPath, FMedSci** UCL Division of Medicine, National Amyloidosis Centre, Royal Free Hospital, London, UK

**Bouke P.C. Hazenberg, MD, PhD** Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

**Guillermo A. Herrera, MD** Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA, USA

**W. Edward Highsmith Jr., PhD** Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA

**Alexander J. Howie, MD, FRCPath** Department of Pathology, University College London, London, UK

**Bertrand L. Jaber, MD, MS** Division of Nephrology, Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA

**Alexandre Karras, MD** Department of Nephrology, AP-HP, University Paris Descartes, Hôpital Européen Georges Pompidou, Paris, France

**Jerry A. Katzmann, PhD** Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

**Christopher J. Klein, MD** Peripheral Nerve Laboratory, Mayo Clinic, Rochester, MN, USA

**Chris P. Larsen, MD** Nephropath, Little Rock, AR, USA

**Francesca Lavatelli, MD, PhD** Department of Molecular Medicine and Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

**John C. Lee, MD** Departments of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA

**John M. Lee, MD, PhD** Department of Pathology and Laboratory Medicine, NorthShore University Health System, Evanston Hospital, Evanston, IL, USA

**Reinhold P. Linke, MD, PhD** Reference Center of Amyloid Diseases amYmed, Innovation Center of Biotechnology, Martinsried, Germany

**Adam J. Loavenbruck, MD, MS** Kennedy Laboratory, Department of Neurology, University of Minnesota, Minneapolis, MN, USA

**Pierluigi Mauri, PhD** Department of Proteomics and Metabolomics, Institute for Biomedical Technologies (ITB-CNR), Segrate (MI), Italy

**Oana Madalina Mereuta, MD, PhD** Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Giampaolo Merlini, MD** Department of Molecular Medicine and Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

**Patrizia Morbini, MD, PhD** Pathology Unit, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

**David L. Murray, MD, PhD** Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

**Mario Nuvolone, MD, PhD** Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland

Amyloidosis Research and Treatment Center, Foundation Scientific Institute Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy

**Laura Obici, MD** Department of Molecular Medicine and Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

**Carl J. O'Hara, MD** Departments of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA, USA

Amyloidosis Center, Boston University School of Medicine, Boston, USA

**Amanda K. Ombrello, MD** Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

**Giovanni Palladini, MD, PhD** Department of Molecular Medicine and Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy

**Marco Paulli** Foundation IRCCS Policlinico San Matteo, Pavia, Italy

Department of Molecular Medicine, University of Pavia, Pavia, Italy

**Maria M. Picken, MD, PhD** Department of Pathology, Loyola University Medical Center, Loyola University Chicago, Maywood, IL, USA

**Emmanuelle Plaisier, MD, PhD** Sorbonne Universités, UPMC Univ Paris 06, UMR\_S 1155, Paris, France

Department of Nephrology and Dialysis, AP-HP, Hôpital Tenon, Paris, France

**Anne Räsänen-Sokolowski, MD, PhD** Transplantation Laboratory-HUSLAB, Helsinki University Central Hospital, Helsinki, HUS, Finland

**Kimiyo M. Raymond, MD** Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

**E. Rene Rodriguez, MD** Department of Pathology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

**Fausto J. Rodriguez, MD** Department of Pathology, Division of Neuropathology, Johns Hopkins Hospital, Baltimore, MD, USA

**Pierre Ronco, MD, PhD** Sorbonne Universités, UPMC Univ Paris 06, UMR\_S 1155, Paris, France

Department of Nephrology and Dialysis, AP-HP, Hôpital Tenon, Paris, France

UMR\_S 1155, Batiment Recherche, Hôpital Tenon, Paris, France

**Filiz Sen, MD** Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

**S. Michelle Shiller, DO** Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA

Department of Surgical Pathology, Baylor University Medical Center, Dallas, TX, USA

**Paweena Susantitaphong, MD, PhD** Division of Nephrology, Department of Medicine, St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA

Extracorporeal Multiorgan Support Dialysis Center, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand

**Carmela D. Tan, MD** Department of Pathology, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA

---

**Tom Törnroth, MD, PhD** Transplantation Laboratory-HUSLAB, Helsinki University Central Hospital, Helsinki, HUS, Finland

**Elba A. Turbat-Herrera, MD** Departments of Pathology and Medicine, Louisiana State University, Shreveport, LA, USA

**Ingrid I. van Gameren, MD, PhD** Department of Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

**Laura Verga, DVM, PhD** Pathology Unit, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

**Per Westermark, MD, PhD** Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden